MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Audio By Carbonatix

NEW YORK--(BUSINESS WIRE)--Feb 20, 2025--

Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 8:00 a.m. ET on Thursday, March 6, 2025 to report financial results for the fourth quarter and year ended December 31, 2024, and discuss recent business updates.

Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, ir.mindmed.co, and archived for at least 30 days after the webcast. Those who plan on participating are advised to join 15 minutes prior to the start time.

About MindMed

MindMed is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health. MindMed trades on Nasdaq under the symbol MNMD.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250220848926/en/

CONTACT: For Media:[email protected]

For Investors:[email protected]

KEYWORD: UNITED STATES NORTH AMERICA CANADA NEW YORK

INDUSTRY KEYWORD: MENTAL HEALTH HEALTH NEUROLOGY OTHER HEALTH PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: Mind Medicine Inc.

Copyright Business Wire 2025.

PUB: 02/20/2025 07:00 AM/DISC: 02/20/2025 07:00 AM

http://www.businesswire.com/news/home/20250220848926/en